DK1418942T3 - Poxvirus-holdige sammensætninger og fremgangsmåde til fremstilling deraf - Google Patents

Poxvirus-holdige sammensætninger og fremgangsmåde til fremstilling deraf

Info

Publication number
DK1418942T3
DK1418942T3 DK02796552T DK02796552T DK1418942T3 DK 1418942 T3 DK1418942 T3 DK 1418942T3 DK 02796552 T DK02796552 T DK 02796552T DK 02796552 T DK02796552 T DK 02796552T DK 1418942 T3 DK1418942 T3 DK 1418942T3
Authority
DK
Denmark
Prior art keywords
poxvirus
freeze
processes
preparation
containing compositions
Prior art date
Application number
DK02796552T
Other languages
Danish (da)
English (en)
Inventor
Karl Heller
Paul Howley
Ingmar Raethe
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1418942(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of DK1418942T3 publication Critical patent/DK1418942T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK02796552T 2001-12-10 2002-11-28 Poxvirus-holdige sammensætninger og fremgangsmåde til fremstilling deraf DK1418942T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200101831 2001-12-10

Publications (1)

Publication Number Publication Date
DK1418942T3 true DK1418942T3 (da) 2005-11-28

Family

ID=8160885

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02796552T DK1418942T3 (da) 2001-12-10 2002-11-28 Poxvirus-holdige sammensætninger og fremgangsmåde til fremstilling deraf

Country Status (22)

Country Link
US (1) US7094412B2 (ru)
EP (1) EP1418942B1 (ru)
JP (1) JP4439263B2 (ru)
KR (1) KR20040074067A (ru)
CN (1) CN1296096C (ru)
AT (1) ATE300954T1 (ru)
AU (1) AU2002361962A1 (ru)
BR (1) BR0214822A (ru)
CA (1) CA2467365C (ru)
DE (1) DE60205388T2 (ru)
DK (1) DK1418942T3 (ru)
EA (1) EA006880B1 (ru)
ES (1) ES2247414T3 (ru)
HK (1) HK1071295A1 (ru)
HU (1) HUP0402179A3 (ru)
IL (2) IL161590A0 (ru)
MX (1) MXPA04005577A (ru)
NO (1) NO20042958L (ru)
NZ (1) NZ533302A (ru)
PL (1) PL213326B1 (ru)
UA (1) UA78738C2 (ru)
WO (1) WO2003053463A2 (ru)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
PL215169B1 (pl) 2002-09-05 2013-10-31 Bavarian Nordic As Sposób amplifikacji wirusów, kompozycja zawierajaca pokswirusa uzyskanego tym sposobem oraz jego zastosowanie do otrzymywania szczepionki
CN1207005C (zh) 2002-10-31 2005-06-22 威世药业（如皋）有限公司 含生物活性物质的兔皮和其用途
WO2006029467A1 (en) * 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
JP5138601B2 (ja) * 2005-11-21 2013-02-06 サノフィ パストゥール リミテッド 組換えウイルス安定化製剤
NZ578960A (en) 2007-05-14 2012-11-30 Bavarian Nordic As Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
DK2148923T3 (da) * 2007-05-18 2012-12-03 Medimmune Llc Konservering af biologisk aktive materialer med frysetørret skum
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
CA2767924A1 (en) 2009-10-08 2011-04-14 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
WO2011145013A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. Parapoxvirus vectors containing rabies virus antigen
CA2804890A1 (en) 2010-07-20 2012-01-26 Ah Usa 42 Llc Parapoxvirus vectors
WO2012010280A1 (en) 2010-07-20 2012-01-26 Bavarian Nordic A/S Method for harvesting expression products
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
US10357555B2 (en) 2012-07-10 2019-07-23 Transgene Sa Mycobacterial antigen vaccine
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
EP3092000A1 (en) 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
WO2015136056A1 (en) 2014-03-12 2015-09-17 Bavarian Nordic A/S Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus
CA3190510A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
WO2016087457A1 (en) 2014-12-01 2016-06-09 Transgene Sa Stable liquid vaccinia virus formulations
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
TW201825674A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
US20190330655A1 (en) 2016-12-28 2019-10-31 Transgene Sa Oncolytic viruses and therapeutic molecules
AU2018269319A1 (en) 2017-05-15 2019-11-07 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3624845A1 (en) * 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
MA49397A (fr) 2017-06-15 2020-04-22 Bavarian Nordic As Vecteurs à poxvirus codant pour des antigènes du vih, et leurs procédés d'utilisation
WO2018234506A2 (en) 2017-06-21 2018-12-27 Transgene Sa PERSONALIZED VACCINE
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
EP3762020A1 (en) 2018-03-07 2021-01-13 Transgene Parapoxvirus vectors
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
JP7437385B2 (ja) 2018-09-06 2024-02-22 バヴァリアン・ノルディック・アクティーゼルスカブ 保管が改善されたポックスウイルス組成物
JPWO2020090871A1 (ja) 2018-10-30 2021-10-07 国立大学法人 東京大学 がん治療のための腫瘍溶解性ウイルス
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
WO2020136235A1 (en) 2018-12-28 2020-07-02 Transgene Sa M2-defective poxvirus
EP4117722A1 (en) 2020-03-12 2023-01-18 Bavarian Nordic A/S Compositions improving poxvirus stability
EP4178605A1 (en) 2020-07-13 2023-05-17 Transgene Treatment of immune depression
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2024003239A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
WO2024003238A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S Epstein-barr-virus vaccine
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
TW202413636A (zh) 2022-08-18 2024-04-01 法商傳斯堅公司 嵌合痘病毒

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (ru)
US4380582A (en) * 1965-07-09 1983-04-19 The United States Of America As Represented By The Secretary Of The Army Preparation of dry variola virus
FR7773M (ru) * 1968-06-14 1970-03-23
US3577526A (en) * 1969-06-13 1971-05-04 Merieux Inst Stabilized smallpox vaccine
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
CA2158935A1 (en) 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
US6869793B2 (en) * 1996-09-24 2005-03-22 Bavarian Nordic Research Institute Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
GB9808922D0 (en) 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors

Also Published As

Publication number Publication date
NZ533302A (en) 2005-11-25
NO20042958L (no) 2004-07-09
HUP0402179A2 (hu) 2005-01-28
CN1602205A (zh) 2005-03-30
EP1418942A2 (en) 2004-05-19
WO2003053463A3 (en) 2004-03-04
ES2247414T3 (es) 2006-03-01
WO2003053463A2 (en) 2003-07-03
EP1418942B1 (en) 2005-08-03
MXPA04005577A (es) 2005-04-19
CA2467365C (en) 2012-11-20
US7094412B2 (en) 2006-08-22
EA006880B1 (ru) 2006-04-28
PL213326B1 (pl) 2013-02-28
BR0214822A (pt) 2004-12-14
CA2467365A1 (en) 2003-07-03
IL161590A0 (en) 2004-09-27
DE60205388T2 (de) 2006-03-30
DE60205388D1 (de) 2005-09-08
US20050019349A1 (en) 2005-01-27
PL369954A1 (en) 2005-05-02
ATE300954T1 (de) 2005-08-15
UA78738C2 (en) 2007-04-25
JP2005513109A (ja) 2005-05-12
AU2002361962A1 (en) 2003-07-09
JP4439263B2 (ja) 2010-03-24
EA200400796A1 (ru) 2004-12-30
HUP0402179A3 (en) 2012-09-28
HK1071295A1 (en) 2005-07-15
IL161590A (en) 2009-06-15
CN1296096C (zh) 2007-01-24
KR20040074067A (ko) 2004-08-21

Similar Documents

Publication Publication Date Title
DK1418942T3 (da) Poxvirus-holdige sammensætninger og fremgangsmåde til fremstilling deraf
NZ596367A (en) Lyophilized therapeutic peptibody formulations
GB0119011D0 (en) Treatment of nail infections
HK1060694A1 (en) Herbal compositions useful as chemopreventive and therapeutic agents.
MXPA01006917A (es) Composicion topica que comprende n-acetilaldosaminas o acidos n-acetilaminos.
BR0315767A (pt) Composição imunogência, método para fabricar uma vacina, kit, vacina, recipiente com uma superfìcie interna repelente à água, e, método para preservar uma composição que compreende ipv e um agente estabilizador
AR039688A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
WO2004060059A3 (en) Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
BRPI0915696B8 (pt) composição de vacina de rotavírus liofilizada e método de preparar a referida composição
GT200100126A (es) Preparaciones de retardo de antibioticos de quinolona y procedimiento para su fabricacion.
WO2004080415A3 (en) Gel composition and method for treatment of vaginal infections
CN104606101A (zh) 一种辣木面膜
BR0208411A (pt) Composto, composição farmacêutica tópica e método para tratamento profilático ou terapêutico de doenças sexualmente transmitidas em um paciente humano, e, uso de um composto
ITMI20031640A1 (it) Base per gel bioadesivi.
NZ528544A (en) Formulations comprising entrapped active ingredients and uses thereof
EP1905449A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
AU2001256384A1 (en) Cosmetic or dermatological cream composition, the preparation and the use thereof
WO2023150771A3 (en) Pharmaceutical composition for treatment and prevention of coronavirus infection
WO2003105672A3 (en) COMPOSITIONS AND METHODS OF CRYOSURGERY
ATE271876T1 (de) Verwendung einer synergistischen zusammensetzung zur herstellung eines medikaments zur behandlung von lebererkrankungen
DOP2001000210A (es) Uso de cepas de parapoxvirus ovis contra la fibrosis de organos
MD2789F1 (en) Entomologic antioxidant and immunomodulating preparation
CN105326762A (zh) 一种芦荟保湿护手霜
WO2001051080A3 (en) Methods and compositions for obtaining disease protection for animals
UA41161A (ru) Состав для лечения пародонтита